CHUC Charlie's Holdings, Inc.
Medicinal Chemicals & Botanical Products · OTC · SEC CIK 1134765 · Fiscal year ends 12/31
Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY266.1%
TTM net income YoY-222.5%
TTM EPS YoY-171.4%
Revenue 3-yr CAGR9.2%
Net income 3-yr CAGR—
Margins
Gross margin27.4%
Operating margin-10.8%
Net margin-7.9%
FCF margin—
EBITDA margin-10.7%
Returns
ROE-73.5%
ROA-20.9%
ROIC (approx.)-126.2%
Asset turnover2.63x
Leverage & solvency
Liabilities / assets75.5%
Debt / equity0.00x
Current ratio1.65x
Interest coverage-9.86x
Cash quality & payout
Operating cash flow / net income2.15x
Accruals ratio23.9%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $20.92M | $7.76M | $16.25M | $26.42M | $21.50M |
| Cost of revenue | $15.26M | $4.89M | — | — | — |
| Gross profit | $5.66M | $2.88M | — | — | — |
| R&D expense | — | — | $169,000 | $804,000 | $24,000 |
| SG&A expense | $6.37M | $5.61M | $6.97M | $8.38M | $8.75M |
| Operating income | -$2.17M | -$3.30M | -$2.20M | -$1.80M | $565,000 |
| Interest expense | $692,000 | $703,000 | $477,000 | $155,000 | $34,000 |
| Pretax income | $4.59M | -$4.00M | -$2.09M | -$1.68M | $5.15M |
| Income tax | $275,000 | $0 | $0 | -$92,000 | $342,000 |
| Net income | $4.50M | -$4.16M | -$2.09M | -$1.59M | $4.81M |
| EBITDA | -$2.13M | -$3.20M | -$2.05M | -$1.51M | $775,000 |
| EPS (basic) | 0.02 | -0.02 | -0.01 | -0.01 | 0.02 |
| EPS (diluted) | 0.02 | -0.02 | -0.01 | -0.01 | 0.01 |
| Weighted avg. shares (diluted) | 278.54M | 234.80M | 216.05M | 212.27M | 237.69M |
| Balance sheet | |||||
| Cash & equivalents | $1.32M | $211,000 | $367,000 | $257,000 | $866,000 |
| Receivables | $440,000 | $331,000 | $289,000 | $1.16M | $1.37M |
| Inventory | $6.72M | $2.13M | $3.83M | $3.65M | $5.00M |
| Current assets | $10.77M | $3.72M | $5.09M | $5.85M | $7.99M |
| PP&E, net | $37,000 | $53,000 | $157,000 | $311,000 | $431,000 |
| Total assets | $11.56M | $3.94M | $5.77M | $7.06M | $9.25M |
| Current liabilities | $7.63M | $5.58M | $4.75M | $4.78M | $5.53M |
| Long-term debt | — | $2.16M | $2.46M | $1.45M | $150,000 |
| Total debt | — | $2.16M | $2.46M | $1.45M | $150,000 |
| Total liabilities | $8.14M | $5.72M | $5.88M | $5.36M | $6.12M |
| Shareholders' equity | $3.42M | -$1.78M | -$107,000 | $1.70M | $3.13M |
| Net debt | — | $1.95M | $2.10M | $1.19M | -$716,000 |
| Shares outstanding | 270.65M | 257.29M | 228.54M | 219.16M | 210.89M |
| Cash flow statement | |||||
| Operating cash flow | -$5.78M | -$1.62M | -$783,000 | -$1.72M | -$1.35M |
| Capital expenditure | $23,000 | $0 | $0 | $189,000 | $110,000 |
| Free cash flow | -$5.80M | -$1.62M | -$783,000 | -$1.91M | -$1.46M |
| Investing cash flow | $7.48M | $0 | $0 | -$189,000 | -$110,000 |
| Financing cash flow | -$590,000 | $1.47M | $893,000 | $1.30M | $901,000 |
| Depreciation & amortization | $39,000 | $102,000 | $154,000 | $296,000 | $210,000 |
| Stock-based compensation | $186,000 | $230,000 | $286,000 | $161,000 | $552,000 |
| Dividends paid | — | — | — | $0 | $883,000 |
Free plan shows the latest 5 periods; Pro shows all 18 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.